ArticleGenome medicine2019
Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma.
Article in Genome medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis: a systematic review including evidence from Japan.Surgery today · 2021Pooled it
- A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma.Nature communications · 2024Trial
- Research progress on the regulation of mesothelioma driven by deubiquitinating enzyme BAP1.Clinical and experimental medicine · 2026Review
- BAP1 Loss Might Be a Predictive Biomarker for Immunotherapy Response in Pleural Mesothelioma.Thoracic cancer · 2026Article
- Malignant craniopharyngiomas: Institutional experience and literature review.Brain pathology (Zurich, Switzerland) · 2026Review
- Multidimensional immune ecological subtyping identifies RUNX1 as a prognostic factor in uveal melanoma.Discover oncology · 2026Article
- BRCA1-Associated Protein 1 (BAP1) in Human Cancer and its Emerging Role as a Novel Potential Therapeutic Target.Current oncology reports · 2026Review
- Tumor suppressor BAP1 emerges as a key regulator of metabolism and cell death in tumors.Frontiers in cell and developmental biology · 2026Review
- BAP1 Mutations and Pleural Mesothelioma: Genetic Insights, Clinical Implications, and Therapeutic Perspectives.Cancers · 2025Review
- Loss of histone deubiquitinase Bap1 triggers anti-tumor immunity.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Case Report: Advanced grade 2 meningioma withFrontiers in oncology · 2025Article
- BAP1 regulates HSF1 activity and cancer immunity in pancreatic cancer.Journal of experimental & clinical cancer research : CR · 2024Article
- Characterizing soluble immune checkpoint molecules and TGF-βScientific reports · 2024Observational
- Targeted Therapy in Mesotheliomas: Uphill All the Way.Cancers · 2024Review
- BAP1 Deficiency Inflames the Tumor Immune Microenvironment and Is a Candidate Biomarker for Immunotherapy Response in Malignant Pleural Mesothelioma.JTO clinical and research reports · 2024Article
- Clinical and genetic characteristics ofFrontiers in immunology · 2024Article
- Novel genetic alterations in liver cancer distinguish distinct clinical outcomes and combination immunotherapy responses.Frontiers in pharmacology · 2024Article
- Major response of a peritoneal mesothelioma to nivolumab and ipilimumab: a case report, molecular analysis and review of literature.Frontiers in oncology · 2024Article
- Peritoneal papillary mesothelioma in situ: BAP1 mutation with indolent behavior for 15 years.Virchows Archiv : an international journal of pathology · 2023Article
- Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesothelioma.Cell reports. Medicine · 2023Article
Corrections and comments
- Comment on
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
As trials of immune checkpoint inhibitor (ICI) therapies demonstrate responses in only a minority of pleural mesotheliomas (PlMs) and largely exclude patients with the related peritoneal mesothelioma (PeM), clinicians need predictive biomarkers of response and inclusion of PeM patients in future trials. A new study finds that loss of the deubiquitinase BAP1 in PeM correlates with an inflammatory tumor microenvironment, suggesting that BAP1 status might identify PeM, and possibly PlM, patients who would benefit from ICI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.